Elismetrep

CAS No. 1400699-64-0

Elismetrep( —— )

Catalog No. M34236 CAS No. 1400699-64-0

Elismetrep (MT-8554) is an orally available TRPM8 inhibitor with potential analgesic activity for the study of vasomotor symptoms in postmenopausal women.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 297 In Stock
10MG 466 In Stock
25MG 928 In Stock
50MG 1200 In Stock
100MG 1646 In Stock
200MG 2223 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Elismetrep
  • Note
    Research use only, not for human use.
  • Brief Description
    Elismetrep (MT-8554) is an orally available TRPM8 inhibitor with potential analgesic activity for the study of vasomotor symptoms in postmenopausal women.
  • Description
    Elismetrep (MT-8554) is an orally available TRPM8 inhibitor with potential analgesic activity for the study of vasomotor symptoms in postmenopausal women.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    TRP/TRPV Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1400699-64-0
  • Formula Weight
    542.53
  • Molecular Formula
    C27H21F3N2O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)C1=CC=C(C=C1)S(=O)(=O)N(C=2N=CC3=CC=CC=C3C2C4CC4)CC5=CC=C(OC(F)(F)F)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • TRPV4 agonist-1 free...

    TRPV4 agonist-1 free base?is an agonist of transient receptor potential vanilloid 4 (TRPV4;EC50 of 60 nM, in the hTRPV4 Ca2+ assay).

  • RN9893

    RN9893 is a selective and potent TRPV4 receptor antagonist with IC50 values of 320, 420 and 660 nM for TRPV4 receptors in mouse, human and rat, respectively.

  • UNC-2025

    UNC-2025( IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.